{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:06:07Z","timestamp":1783515967259,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.urolonc.2024.01.016","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T17:11:58Z","timestamp":1707498718000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical\/treatment relevance"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-204X","authenticated-orcid":false,"given":"Jonathon","family":"Mahlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.01.016_bib0001","first-page":"51","article-title":"The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis","volume":"6","author":"Aly","year":"2020","journal-title":"J Clin Pathw"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0003","series-title":"Urinary and Male Genital Tumors","year":"2022"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0004","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41379-019-0403-9","article-title":"Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"33","author":"Varma","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0006","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","article-title":"The impact of histological reclassification during pathology re-review\u2013evidence of a Will Rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0008","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.euf.2017.06.013","article-title":"The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy","volume":"5","author":"Li","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0009","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0011","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2020.07.006","article-title":"Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin","volume":"102","author":"Sangoi","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0013","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bju.15428","article-title":"Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy","volume":"129","author":"Almassi","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0014","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0015","first-page":"205","article-title":"Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder","volume":"10","author":"Sanguedolce","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0016","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41379-020-0453-z","article-title":"PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates","volume":"33","author":"Taylor","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0017","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/PAS.0b013e3181cd385b","article-title":"Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis","volume":"34","author":"Lopez-Beltran","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0018","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/PAS.0b013e31820f709e","article-title":"Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features","volume":"35","author":"Williamson","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ajpath.2019.09.007","article-title":"RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype","volume":"190","author":"Manocha","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/his.12785","article-title":"Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation","volume":"68","author":"Samaratunga","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0021","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2012.04.020","article-title":"The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma","volume":"188","author":"Kim","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0023","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jcp.2006.038802","article-title":"Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry","volume":"60","author":"Lopez-Beltran","year":"2007","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.016_bib0024","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1016\/j.clgc.2017.07.008","article-title":"Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder","volume":"15","author":"Minato","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes","volume":"81","author":"Sjodahl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0026","article-title":"Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype","volume":"6","author":"Almassi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0027","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)44882-8","article-title":"Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies","volume":"136","author":"Dexeus","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0028","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/bjc.2014.89","article-title":"Serum total hCGbeta level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract","volume":"110","author":"Douglas","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0029","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.mce.2006.02.019","article-title":"Ectopic hCGbeta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis","volume":"260-262","author":"Iles","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA\/SUO Guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0031","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","article-title":"Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas","volume":"42","author":"Ju","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0032","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.urology.2022.02.006","article-title":"Immunohistochemical screening of upper tract urothelial carcinomas for lynch syndrome diagnostics: a systematic review","volume":"165","author":"Rasmussen","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0033","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0034","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0035","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0002-9440(10)62369-3","article-title":"Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma","volume":"166","author":"Cheng","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0036","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","article-title":"Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy","volume":"20","author":"Teo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0037","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","article-title":"Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center","volume":"64","author":"Lynch","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0039","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41416-018-0229-0","article-title":"Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy","volume":"119","author":"Rose","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0040","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0041","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1002\/cncr.33071","article-title":"A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma","volume":"126","author":"McPherson","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0042","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0043","article-title":"Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","volume":"7","author":"Doroshow","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0044","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/cncr.31817","article-title":"Mocetinostat for patients with previously treated, locally advanced\/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes","volume":"125","author":"Grivas","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0045","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0046","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0047","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0048","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0049","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0050","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0051","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Human Pathology"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0052","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1541-7786.MCR-20-0751","article-title":"Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes","volume":"19","author":"Alhalabi","year":"2021","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0053","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non\u2013Muscle-Invasive Bladder Cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Research"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0054","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0056","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0057","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability","volume":"75","author":"Kim","year":"2019","journal-title":"European Urology"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0058","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1\/PD-L1 Blockade in Advanced Urothelial Cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2024.01.016_bib0059","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2023.41.16_suppl.4511","article-title":"Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0060","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0061","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0062","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0063","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0064","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.016_bib0066","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-020-02787-8","article-title":"Comparative genomic profiling of glandular bladder tumours","volume":"477","author":"Maurer","year":"2020","journal-title":"Virchows Arch"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T20:24:57Z","timestamp":1728937497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1078143924000176"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical\/treatment relevance","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}